Top Markets
#1 Purr Purr +62.18%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +27.54%
#4 Kinetiq Kinetiq +24.51%
#5 ApeX ApeX +23.35%
#6 Fake World Assets Fake World Assets +19.18%
#7 Zora Zora +18.85%
#8 Non-Playable Coin Non-Playable Coin +18.72%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.50%
#10 OriginTrail OriginTrail +18.33%
Coin of the day
Purr Purr
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Peringkat dalam Saham #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Harga Saham
$2.72
Terakhir disinkronkan: 2023-10-19
Kapitalisasi Pasar
$111.47M
Perubahan (1 hari)
-0.73%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Talaris Therapeutics, Inc. (TALS)

Kategori

Healthcare
Pendapatan untuk Talaris Therapeutics, Inc. (TALS)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari Talaris Therapeutics, Inc., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Talaris Therapeutics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH